1. Introduction {#sec1}
===============

Circular RNAs (circRNAs), which contain a covalently closed continuous loop, are an abundant class of endogenous RNAs that are formed during the maturation of precursor mRNA. CircRNAs are widely expressed in eukaryotes, are evolutionarily conserved, and can be specific to certain cell types or developmental stages. In addition, circRNAs have been found in the nucleus and mitochondria. Unlike linear RNA, circRNAs have no 5′ cap or 3′ tail structure and is not easily degraded by the exonuclease RNase R, which is stable in cells \[[@B1]--[@B3]\]. The formation mechanism of circRNAs also determines its diverse and complex biological functions \[[@B4]--[@B7]\]. Among them, its characteristics of transcription, translation, protein interaction, and signal transduction regulation have been confirmed by a growing number of studies \[[@B3], [@B8]\]. In particular, circRNAs can specifically change the biological behaviour of cells in tissues and in diseases \[[@B3]\]. Moreover, many studies have shown that circRNAs are widely and specifically expressed in tumours, ageing, diabetes, cardiovascular and cerebrovascular diseases, and skin diseases \[[@B1], [@B7], [@B9]--[@B11]\]. These results offer a new perspective on biomolecular science.

Acute coronary syndrome (ACS) can lead to a series of acute cardiovascular events, such as arrhythmia, heart failure, and even sudden death. Its main pathogenesis is closely related to plaque rupture, vasospasm, platelet aggregation, and thrombosis. However, the mechanism remains unclear. With the rapid development of next-generation gene sequencing technology, an increasing number of reports have indicated that noncoding RNAs (ncRNAs), such as circRNAs, microRNAs (miRNAs), and long noncoding RNAs (lncRNAs), have a significant influence on cardiovascular diseases \[[@B12]\]. CircRNAs, as regulators of gene expression, may be an important genetic mechanism underlying the pathogenesis of multifactorial complex diseases \[[@B10], [@B13]--[@B16]\]. Thus, elucidating the process by which miRNAs regulate the gene expression and the specificity of the regulated targets is highly important for probing the mechanism underlying ACS \[[@B17]\]. However, few studies have investigated whether circRNAs and miRNAs are involved in the occurrence and development of ACS. The results of our previous work have indicated that circRNAs are significantly expressed in the blood of patients with coronary heart disease (CHD) \[[@B18]\].Thus, in this work, we screened the characteristic circRNA and miRNA expression profiles of ACS using a microarray gene chip and predicted the possible circRNA-miRNA interaction. We aimed to provide critical information for investigations into the complex regulatory mechanisms of ACS.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

We included inpatients diagnosed with ACS (I24.901), including those diagnosed with acute myocardial infarction (AMI) (I21) and unstable angina pectoris (UAP) (I20.001) according to the criteria of the International Classification of Diseases--10th edition, who were treated at the Department of Cardiology of the First Affiliated Hospital of Xinxiang Medical College between November 2016 and February 2017. The diagnostic criteria for AMI and UAP were based on the globally harmonized definition of AMI and on the 2012 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-elevation Myocardial Infarction \[[@B19]--[@B21]\]. All participants underwent coronary angiography (CAG), and Gensini scores (GS) were calculated. Patients with the following characteristics were excluded: (1) severe congestive heart failure, malignant hypertension, severe arrhythmia, or severe lung dysfunction; (2) severe neurosis, hyperthyroidism, cervical spondylosis, hepatobiliary disease, gastric and oesophageal reflux, or chest pain caused by nonangina pectoris; (3) AMI/UAP complicated by severe primary diseases such as those of the liver, kidney, or haematopoietic system; (4) mental illness; (5) current pregnancy or lactation; (6) allergies to iodine or contrast agents or the allergic physique; and (7) various infectious diseases. Ultimately, 15 inpatients were selected and subsequently divided into the CG (control group), UAP group, and AMI group (5 patients per group). The CG was filtered according to baseline data such as the clinical CAG score (GS \< 2). Then, we collected the participants\' baseline data.

This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical College (approval number: 2016039).

2.2. Plasma Sample Collection and CircRNA-miRNA Microarray Analysis {#sec2.2}
-------------------------------------------------------------------

Five millilitres of whole blood was collected into an anticoagulant tube containing ethylenediaminetetraacetic acid (EDTA). The blood samples were stored in an ice box at 4°C and transported to the Heart Center of Xinxiang Medical University. Total RNA was extracted from 250 *μ*l of whole blood with a 750 *μ*l extraction kit (TRIpure LS Reagent, CapitalBio, Beijing, China) and was cryopreserved at −80°C. Total RNA was extracted and reverse transcribed for the synthesis of first- and second-strand cDNA. *In vitro* transcription and synthesis of cRNA were conducted, and cRNA was transcribed to generate cDNA, which was simultaneously fluorescently labelled using the Ambion WT Expression kit. A Crystal Core® CapitalBiotech Human CircRNA Array V2.0 (4 × 180 K) chip was used to analyse circRNAs. The circRNA target sequences were all from circBase (<http://www.circbase.org/>) and deepBase (<http://rna.sysu.edu.cn/deepBase/browser.php>). Human miRNA Microarray chips (8 × 60 K) (release 21.0; Agilent Technologies, Inc., Santa Clara, CA, USA) were used for the microarray analysis. The raw data were normalized by the quantile algorithm using GeneSpring Software v12.6 (Agilent Technologies, Inc.) \[[@B22], [@B23]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

Image data of the hybridized microarray (Agilent Human CircRNA Array V2.0) in tiff format were analysed by Agilent Feature Extraction (V10.7) software, and the data were extracted. Then, the circRNA array data used threshold fold change (FC) values of ≥2 and ≤−2 and a *t* test *P* value of 0.05, and miRNA array data FC ≥ 1.2 and ≤−1.2 and a *t* test *P* value of 0.05, and circRNAs and miRNAs were analysed for data summarization, normalization, and quality control by using GeneSpring GX software (Agilent). To select the differentially expressed genes, data normalization and quality control analysis were performed for each sample. CLUSTER 3.0 software was used for data analysis and graphical display. MiRanda-3.3 software was used to predict the circRNAs that may bind miRNAs and to construct a network diagram though the open-source bioinformatics software Cytoscape. In a network analysis, a degree of centrality is defined as the number of linkages one node has to another. A degree is the simplest and most important measure of gene centrality within a network for determining the relative importance. Gene ontology (GO), pathway, and disease enrichment analyses were conducted for differentially expressed circRNAs with Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology-Based Annotation System (KOBAS) software. The processing and sorting of circRNA and miRNA expression profile chip data were performed in whole or in part with the CapitalBio Technology Expression Spectrum Chip Analysis System V1.0 (computer software copyright registration number: 2014SR122558) \[[@B15], [@B22], [@B23]\].

Statistical analyses of baseline data were performed using SPSS 22.0, and all data are presented as the means ± standard deviations ($\overline{x} \pm s$).

3. Results {#sec3}
==========

3.1. Baseline Data {#sec3.1}
------------------

[Table 1](#tab1){ref-type="table"} outlines the patient characteristics. Patients with AMI had lower blood pressure values and higher levels of blood glucose and myocardial enzymes than patients with UAP (*P* \< 0.05). There was no significant change in blood lipid biochemistry. Patients with UAP had a calculated GS of \>15 and those with AMI had a GS of \>40, as evidenced by CAG. The GSs in the UAP and AMI groups were higher than those in the CG.

3.2. CircRNA and miRNA Expression Profiling {#sec3.2}
-------------------------------------------

To identify whether circRNAs and miRNAs are differentially expressed in ACS, we extracted total RNA from the peripheral blood of 5 AMI patients, 5 UAP patients, and 5 CG with matched clinical and statistical characteristics and analysed the samples using a microarray gene chip. The detected circRNAs were differentially expressed among the groups ([Figure 1](#fig1){ref-type="fig"}). A total of 266 circRNAs (121 upregulated and 145 downregulated) were predicted in the AMI and UAP groups (*P* \< 0.05, FC ≥2) (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}). The data were log2-transformed and median centred by gene using the Adjust Data function in CLUSTER 3.0 software and then further analysed with hierarchical clustering with average linkage criterion (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

Three miRNAs were differentially expressed in the AMI and UAP groups compared with those in the CG: hsa-miR-4299 was upregulated, and hsa-miR-20b-5p and hsa-miR-363-3p were downregulated (*P* \< 0.05, FC ≥ 1.2) ([Table 4](#tab4){ref-type="table"}).

3.3. Correlation Analysis of the circRNA-miRNA Network {#sec3.3}
------------------------------------------------------

CircRNAs are significant influencing factors in miRNA function and transcriptional control by acting as sponges, competing endogenous RNAs, or positive regulators of their parent coding genes. In this study, we utilized miRanda software to construct the circRNA-miRNA network, and these circRNA-miRNA pairs were screened though the open-source bioinformatics software Cytoscape. We constructed a network that matched the differentially expressed circRNAs by cross comparing the biological information among the AMI-UAP network, the AMI-CG network, the UAP-CG network, and the AMI-CG-UAP network. A large number of circRNAs that were predicted to bind to miRNAs with a combined weight score of 1 were screened as differentially expressed genes.

Specifically, of the many circRNAs predicted to bind to miRNAs, not only did a single circRNA bind more than 1--100 miRNAs, but more than 1--100 circRNAs also bound a single miRNA, such as hsa_circ_8316-4, hsa-circ_0097809, hsa_circ_0097811, hsa_circ_0097810, hsa_circ_0139861, and hsa_circ_0140538, with significantly decreased expression, and hsa-circ_0140759, hsa_circ_0140758, hsa_circ_16316-13, hsa_circ_0140760, and as well as other circRNAs with significantly increased expression. Multiple miRNAs had a common locus for binding to the same circRNA, and vice versa. These results suggested that circRNAs exhibited coexpression correlations with miRNAs and that circRNAs could act as source genes to interact with miRNAs to regulate the occurrence and development of ACS (Figures [2](#fig2){ref-type="fig"}[](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}). All differentially expressed circRNAs are presented in [Table 5](#tab5){ref-type="table"}. Simultaneously, miRNAs could act as target genes to interact with copious circRNAs ([Table 6](#tab6){ref-type="table"}, Figures [6](#fig6){ref-type="fig"}[](#fig7){ref-type="fig"}[](#fig8){ref-type="fig"}--[9](#fig9){ref-type="fig"}). However, how these novel genes participate in the process of disease development is still unclear. Further cells culture or animal experiments are needed to verify these findings.

3.4. CircRNA Enrichment Analyses {#sec3.4}
--------------------------------

To better understand the functions of the genes associated with the differentially expressed circRNAs, GO ([Figure 10](#fig10){ref-type="fig"}), disease ([Figure 11](#fig11){ref-type="fig"}), and pathway ([Figure 12](#fig12){ref-type="fig"}) enrichment analyses were performed with KOBAS software. Pathway and disease terms were selected from the first 30 significantly enriched terms. GO analysis was used to select the first 30 significantly enriched biological process (BP), molecular function (MF), and cellular component (CC) terms, and a histogram was drawn according to the *P* values, which directly reflected the significantly enriched terms.

3.5. GO Enrichment Analysis {#sec3.5}
---------------------------

We carried out KEGG pathway mapping based on the encyclopaedia\'s orthology terms to assess related pathways correlating with differentially expressed circRNAs from the AMI and UAP groups compared with those from the CG. A total of 53 MF terms, 241 BP terms, and 35 CC terms were significantly enriched (*P* \< 0.05). These three major categories define and describe various aspects of a gene\'s function. We selected the first 30 significantly enriched terms from the three categories and plotted a histogram according to the *P* values, which directly reflect the significantly enriched terms (*P* \< 0.05; [Figure 10](#fig10){ref-type="fig"}). The top-ranking GO terms involved in ACS included the metabolic process (GO:0008152), cellular process (GO:0009987), single organism process (GO:0044699), organelle (GO:0043226), cell (GO:0005623), cell part (GO:0044464), and binding (GO:0005488).

3.6. Disease Enrichment Analysis {#sec3.6}
--------------------------------

Disease enrichment analysis was performed using the NHGRI GWAS Catalog. A total of 19 terms were significantly enriched (*P* \< 0.05). The diseases predicted to be associated with ACS included cardiovascular disease risk factors and high-density lipoprotein cholesterol (HDL-C).

The differentially expressed circRNAs were found to be involved in terms related to cardiovascular diseases, such as bone mineral density (hsa123803), phosphorus levels (hsa221496), metabolite levels (5−HIAA) (hsa4023), tourette syndrome (hsa5251), and anger (hsa56776) (*P* \< 0.05; [Figure 11](#fig11){ref-type="fig"}).

3.7. Pathway Enrichment Analysis {#sec3.7}
--------------------------------

In the KEGG pathway database, 266 circRNAs with different expression levels were enriched, and the first 30 significantly enriched terms were selected (*P* \< 0.05). We found pathways that may be involved in ACS: dilated cardiomyopathy (hsa05141), transcriptional misregulation in cancer (hsa05202), amoebiasis (hsa05146), Fanconi anaemia pathway (hsa03460), hypertrophic cardiomyopathy (hsa05410), and arrhythmogenic right-ventricular cardiomyopathy (hsa05412) (*P* \< 0.05; [Figure 12](#fig12){ref-type="fig"}).

4. Discussion {#sec4}
=============

Accumulating evidence suggests that ncRNA participates in diseases such as cardiovascular diseases, diabetes mellitus, and hypertension. Recent progress in the ncRNA research field has uncovered central aspects for the regulation and functions of biogenesis and biology in the pathophysiology of the cardiovascular system \[[@B11], [@B12]\]. More importantly, the circRNA-miRNA-mRNA regulatory network plays an important role in the occurrence and development of cardiovascular disease \[[@B11]\].

The research results reported in this paper offer many important findings and imply that circRNA and miRNA are differentially expressed between the ACS groups and the CG. Differential expression was detected for a total of 266 circRNAs, of which 121 were upregulated and 145 were downregulated in the ACS groups (*P* \< 0.05, FC ≥ 2), and the circRNAs were found to be related to UTY, KDM5D, USP9Y, MRPL39, ABCA5, and CCT8 and as well as other genes (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}). In previous studies, a total of 1670 circRNAs were identified in the AMI group (859 upregulated and 811downregulated) and a total of 110 circRNAs were identified in the CHD group (73 upregulated and 73 downregulated) (*P* \< 0.05, FC ≥ 2.0). Furthermore, hsa_circ_16316-13 was found to be significantly increased in CHD patients \[[@B18], [@B24]\]; similarly, hsa \_circ_16316-13 was found to be upregulated in this paper.

To date, many outcomes have confirmed the view that circRNAs can be used as sponges for miRNA to regulate the gene expression. Recent evidence points to a pivotal role for circRNAs in the regulation of miRNA function as miRNA sponges; in addition, they may play a significant role in pathophysiology of cardiovascular diseases \[[@B25]\]. Strikingly, genetic network bioinformatics analysis for ACS revealed not only that a single circRNA could bind to more than 1--100 miRNAs but also more than 1--100 circRNAs bound to a single miRNA (Figures [2](#fig2){ref-type="fig"}[](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}[](#fig6){ref-type="fig"}[](#fig7){ref-type="fig"}[](#fig8){ref-type="fig"}--[9](#fig9){ref-type="fig"}). The results provide evidence to show that circRNA is bound with miRNA in the occurrence and development of ACS. Another study showed that circRNA_101237 acts as a sponge for let-7a-5p, regulating cardiomyocyte death and autophagy; additionally, the circRNA-101237/let-7a-5p/IGF2BP3 (insulin-like growth factor 2 mRNA-binding protein 3) axis serves as a regulator of cardiomyocyte death \[[@B26]\]. CircNCX1 was increased in response to reactive oxygen species and promotes cardiomyocyte apoptosis by competitive binding to miR-133a-3p, suppressing the activity of CDIP1 (a proapoptotic gene cell death-inducing protein) by acting as an endogenous miR-133a-3p sponge \[[@B27]\]. Thus, circRNA-miRNA axes are involved in a series of disease pathways such as myocardial infarction, myocardial hypertrophy, cardiac regeneration, cardiac fibroblasts, and heart failure \[[@B2], [@B25], [@B28]\]. Moreover, targeted localization of circRNA-miRNA-mRNA may be a potential target for cardiovascular disease treatment \[[@B16]\].

The results of the KEGG pathway enrichment analysis revealed that differentially expressed genes are involved in the ACS signalling pathway, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right-ventricular cardiomyopathy ([Figure 12](#fig12){ref-type="fig"}). The dilated cardiomyopathy (DCM) pathway involves proteins such as Desmin, DMD, Titin, Tnt, ACTA1, TPM, Laminac, SGCD, TNF-*α*, IGF-1, TGF-*β*, and Ang-II. Additionally, more valuable in current clinical practice, cTnT is the preferred biochemical marker for myocardial cell necrosis, and alleviated cTnT levels are detected only 3--6 hours after the onset of ischaemic symptoms. Currently, a positive troponin result is associated with clinically important increases in mortality, regardless of age, even if the level is only slightly above normal \[[@B29]\]. In addition, the pathway is related to arrhythmogenic right-ventricular cardiomyopathy in ACS ([Figure 12](#fig12){ref-type="fig"}).

Among the results of the enrichment analysis of 155 diseases, 19 diseases were predicted to be associated with ACS ([Figure 11](#fig11){ref-type="fig"}), such as cardiovascular disease risk factors and HDL-C. Risk factors for ACS are known to include hypertension, hyperlipidaemia, triglycerides, smoking, alcoholism, diabetes, lack of exercise, anger, overweight, and genetic factors. In recent years, many basic science and clinical studies have reported that glycaemic variability \[[@B30]\], impaired spontaneous/endogenous fibrinolytic status \[[@B31]\], low-density lipoprotein (LDL), nonadherence \[[@B32]\], socioeconomic and psychosocial factors, grip strength, household environment, ambient pollution, and sodium intake \[[@B33]\] are highly significant risk factors for cardiovascular disease.

Encouragingly, some of these differentially expressed genes have been validated in cardiovascular diseases. Clinical research conducted by Vilade et al. revealed that hsa_circ_0001445 exists stably in plasma and can serve as a new biomarker for coronary artery disease, as it was associated with a higher extent of coronary atherosclerosis \[[@B34]\]. Recent reports have also suggested that circRNA is another type of large noncoding RNA with translation potential \[[@B35]--[@B37]\]. Sebastiaan van Heesch et al. focused on protein translation in the heart for the first time using a method combining ribosomal imprinting and provided information on protein translation regulation during DCM \[[@B38]\]. Experiments on mice carried out by Garikipati VNS et al. revealed that overexpression of circFndc3b contributed to reducing myocardial and endothelial cell apoptosis and improving myocardial function. Furthermore, circFndc3b interacted with the RNA-binding protein FUS to positively regulate the expression of VEGF-A, thereby improving the function and reconstruction of the myocardium after infarction \[[@B39]\].

In conclusion, circRNAs are involved in the occurrence and development of ACS through multiple points of network correlation for miRNA regulation. We speculate that circRNAs may serve as a potential therapeutic avenue for a pathophysiological mechanism of ACS and may even become diagnostic and therapeutic biomarkers for ACS. In the future, we will perform *in vitro* and *in vivo* tests to further validate the involvement of circRNAs in the atherosclerotic process of ACS.
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*Highlights*. (a) CircRNA and miRNA may be closely related to the pathogenesis of acute coronary syndrome. (b) Based on gene chip analysis, 266 circRNAs and 3 miRNAs were differentially expressed in acute coronary syndrome. (c) A single circRNA can bind to more than 1--100 miRNAs, and vice versa. (d) The metabolism pathways, signalling pathways, and involved diseases affected by these circRNAs were predicted by enrichment analysis.

Ethical Approval
================

This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University.

Consent
=======

The patients in this research provided written consent to participate and had completed clinical data. Signed written informed consent forms were obtained from the patients and/or guardians.

Disclosure
==========

Fei Lin and Guoan Zhao take responsibility for all aspects of the reliability and freedom from bias.

Conflicts of Interest
=====================

The authors declare that they have no conflicts of interest.

Authors\' Contributions
=======================

Guoan Zhao conceived the study. Fei Lin and Yaming Yang drafted the manuscript. Guhao Zhang and Meng Li acquired the data. Quan Guo and Siyu Sun analysed the data. Xiulong Wang, Dongxu Li, and Mingzhang Xie revised the manuscript. All authors read and approved the final manuscript.

![Heatmap of circRNAs with differential expression between groups. The columns represent patients, and the rows represent the degree to which a gene was expressed at different copy numbers. The colour key in the top left indicates the expression level (red indicates upregulation; green indicates downregulation). The expression of circRNAs is hierarchically clustered on the *y*-axis; the corresponding miRNAs are shown at the top. The left-most bar on the *y*-axis indicates the group assignment. The genes in 15 clusters, denoted as CG (a9, a14, H2, H3, H4), AMI (G2, G3, G5, G7, G8) and UAP (a10, a15, Z8, Z10, Z11), included 121 upregulated and 145 downregulated genes.](ECAM2020-1584052.001){#fig1}

![Comparison of circRNA-miRNA prediction network maps between the AMI and UAP group. Prediction of miRNAs that may be bound by circRNA and construction of a circRNA-miRNA network. According to the relationship between circRNAs and target miRNAs, the top circRNAs with the most FCs were selected to construct the circRNA-miRNA network map. The squares represent miRNAs and the pentagrams represent circRNAs, where green indicates downregulation and purple indicates upregulation.](ECAM2020-1584052.002){#fig2}

![Comparison of circRNA-miRNA prediction network maps between the CG and AMI group. Prediction of miRNAs that may be bound by circRNA and construction of a circRNA-miRNA network. According to the relationship between circRNAs and target miRNAs, the top circRNAs with the most FCs were selected to construct the circRNA-miRNA network map. The squares represent miRNAs and the pentagrams represent circRNAs, where green indicates downregulation and purple indicates upregulation.](ECAM2020-1584052.003){#fig3}

![Comparison of circRNA-miRNA prediction network maps between the CG and UAP groups. Prediction of miRNAs that may be bound by circRNA and construction of a circRNA-miRNA network. According to the relationship between circRNAs and target miRNAs, the top circRNAs with the most FCs were selected to construct the circRNA-miRNA network map. The squares represent miRNAs and the pentagrams represent circRNAs, where green indicates downregulation and purple indicates upregulation.](ECAM2020-1584052.004){#fig4}

![Comparison of circRNA-miRNA prediction network maps in the CG and ACS (AMI and UAP) groups. Prediction of miRNAs that may be bound by circRNA and construction of a circRNA-miRNA network. According to the relationship between circRNAs and target miRNAs, the top circRNAs with the most FCs were selected to construct the circRNA-miRNA network map. The squares represent miRNAs and the pentagrams represent circRNAs, where green indicates downregulation and purple indicates upregulation.](ECAM2020-1584052.005){#fig5}

![Comparison of circRNA-miRNA (red-yellow) coexpression maps between the AMI and UAP groups. These images depict the number of circRNAs that can bind to the bound target gene miRNA. The circRNAs have the same trend as miRNA changes, or the correlation is relatively close.](ECAM2020-1584052.006){#fig6}

![Comparison of circRNA-miRNA (red-yellow) coexpression maps between the CG and AMI groups. These images depict the number of circRNAs that can bind to the bound target gene miRNA. The circRNAs have the same trend as miRNA changes, or the correlation is relatively close.](ECAM2020-1584052.007){#fig7}

![Comparison of circRNA-miRNA (red-yellow) coexpression maps between the CG and UAP groups. These images depict the number of circRNAs that can bind to the bound target gene miRNA. The circRNAs have the same trend as miRNA changes, or the correlation is relatively close.](ECAM2020-1584052.008){#fig8}

![Comparison of circRNA-miRNA (blue-red) coexpression maps between the CG, AMI, and UAP groups. These images depict the number of circRNAs that can bind to the bound target gene miRNA. The circRNAs have the same trend as miRNA changes, or the correlation is relatively close.](ECAM2020-1584052.009){#fig9}

![Functional annotation of differentially expressed genes (DEGs). Itshows the enrichment of DEGs compared with the background genes.](ECAM2020-1584052.010){#fig10}

![Functional annotation of differentially expressed genes (DEGs). Disease ontology analysis was used to select the top 30 terms that were significantly enriched, and the *P* values were then used to sort the top plots.](ECAM2020-1584052.011){#fig11}

![Functional annotation of differentially expressed genes (DEGs). The KEGG pathway analysis was used to select the top 30 terms that were significantly enriched, and the *P* values were then used to sort the top plots.](ECAM2020-1584052.012){#fig12}

###### 

Patients characteristics ($\,\overline{x} \pm s$ group *=* 5).

                           CG               UAP              AMI
  ------------------------ ---------------- ---------------- -----------------
  Age (years)              55 ± 11          60 ± 11          54 ± 8
  HR (min)                 66 ± 9           71 ± 13          81 ± 10
  SBP (mmHg)               149 ± 10         146 ± 11         130 ± 15
  DBP (mmHg)               83 ± 12          79 ± 16          75 ± 6
  Glu (3.9--6.1 mmol/L)    5.25 ± 7.82      5.34 ± 0.62      6.46 ± 1.92
  CHO (0--5.2 mmol/L)      3.69 ± 0.88      3.99 ± 1.05      3.81 ± 0.37
  TG (0.7--1.7 mmol/L)     1.26 ± 0.65      1.21 ± 0.41      1.27 ± 0.45
  APOA1 (1--1.76 g/L)      1.13 ± 0.20      1.00 ± 0.10      0.89 ± 0.12
  APOB (0.6--1.14 g/L)     0.72 ± 0.20      0.79 ± 1.84      0.71 ± 0.15
  HDL (0.8--1.55 mmol/L)   1.11 ± 0.18      0.92 ± 0.20      0.95 ± 0.12
  LDL(1.64--3.62 mmol/L)   2.25 ± 0.66      2.54 ± 0.92      2.52 ± 0.44
  AST (15--50 U/L)         21.60 ± 4.98     25.60 ± 4.22     96.80 ± 65.06
  LDH (313--618 U/L)       149.20 ± 17.20   162.60 ± 29.59   449.00 ± 265.70
  CK (55--170 U/L)         48.00 ± 13.21    70.80 ± 35.09    817.60 ± 535.16
  CK-MB (0--25 U/L)        15.80 ± 7.22     16.80 ± 4.23     74.40 ± 48.55
  Gensini score (%)        1.00 ± 1.41      65.40 ± 49.09    51.90 ± 10.37

APOA1 = apolipoprotein A1; APOB = apolipoprotein B; CHO = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; AST = aspartate transaminase; LDH = lactate dehydrogenase; CK = creatine kinase; CK-MB = creatine kinase isoenzyme MB.

###### 

Expression profiles of 121 circRNAs that were upregulated (*P* \< 0.05, FC ≥ 2).

  No.      ProbeName          *P*       FC (abs)   geneSymbol   circStart   circEnd    Strand   miRNA number   miRNA number more than 1
  -------- ------------------ --------- ---------- ------------ ----------- ---------- -------- -------------- --------------------------
  1        hsa-circ16316-10   0.00183   156.1532   UTY          15447442    15481229   −        100            17
  2        hsa_circ0140759    0.00078   145.55     UTY          15466882    15481229   −        95             6
  3        hsa_circ0140760    0.00139   93.25378   UTY          15467172    15471765   −        100            66
  4        hsa-circ16316-13   0.00141   88.45529   UTY          15447442    15478273   −        100            17
  5        hsa_circ0140758    0.00147   80.8945    UTY          15447442    15448215   −        100            3
  6        hsa-circ16316-4    0.00199   61.61567   UTY          15466882    15472408   −        85             5
  7        hsa-circ16316-11   0.00116   44.99736   UTY          15471646    15471866   −        11             ---
  8        hsa_circ0140781    0.00129   26.7885    KDM5D        21901413    21903743   −        49             1
  9        hsa_circ0140736    0.00149   24.01664   USP9Y        14821320    14885859   \+       100            7
  10       hsa_circ0003368    0.00689   22.6279    UTY          15478146    15481229   −        9              ---
  11       hsa-circ16316-9    0.00064   21.13425   UTY          15435434    15438230   −        43             4
  12       hsa_circ0009024    0.00047   17.24446   ---          21749095    21749393   \+       25             ---
  13       hsa_circ0140746    0.00106   16.81741   USP9Y        14870435    14885859   \+       42             ---
  14       hsa-circ16316-2    0.00316   16.45998   UTY          15435434    15481229   −        100            24
  15       hsa-circ16316-12   0.00040   15.87258   UTY          15435434    15448215   −        100            7
  16       hsa_circ0140783    0.00160   15.52771   ---          22669237    22683186   −        100            100
  17       hsa-circ16316-1    0.01056   14.98803   UTY          15478146    15508852   −        12             ---
  18       hsa_circ0007907    0.00053   13.54894   ZFY          2829114     2829687    \+       25             ---
  19       hsa_circ0140780    0.00062   12.87783   KDM5D        21901413    21901548   −        12             ---
  20       hsa-circ16316-7    0.00914   12.75820   UTY          15522872    15526673   −        15             ---
  ......   ......                       ......                                                                  
  121      hsa_circ0076034    0.00770   2.00799    LEMD2        33744730    33756906   −        100            100

ProbeName = probe address; FC = fold change; geneSymbol = abbreviated gene name; circStart = gene initiation site; circEnd = gene termination position; strand = circRNA in chain; miRNA number = number of miRNAs that the circRNA can bind to (sorted by the number of binding sites---if greater than 100, only the top 100 binding sites are selected); miRNA number more than 1 = the circRNA can bind to 2 or more miRNAs.

###### 

Expression profiles of 145 circRNAs that were downregulated (*P* \< 0.05, FC ≥ 2).

  No.      ProbeName          *P*        FC (abs)   geneSymbol   circStrat   circEnd     Strand   miRNA number   miRNA number more than 1
  -------- ------------------ ---------- ---------- ------------ ----------- ----------- -------- -------------- --------------------------
  1        hsa_circ0140537    0.001857   66.81375   ---          73044457    73044598    −        6              ---
  2        hsa_cir_0091074    0.001099   62.43283   ---          73048902    73051109    −        59             ---
  3        hsa_circ0140538    0.001115   53.70956   ---          73045949    73051109    −        100            100
  4        hsa_circ0091073    0.001317   38.93487   ---          73040494    73051109    −        100            100
  5        hsa_circ0140539    0.001931   27.13039   ---          73045949    73057338    −        100            100
  6        hsa-circ16166-3    0.001541   23.23273   ---          73050900    73053209    −        39             ---
  7        hsa-circ16166-1    0.001702   20.40522   ---          73050900    73057338    −        50             1
  8        hsa_circ0140540    0.001844   15.58513   ---          73045949    73061308    −        100            100
  9        hsa_circ0140536    0.001075   13.07049   ---          73044087    73044570    −        16             ---
  10       hsa_circ0140541    0.00105    6.618035   ---          73046801    73046954    −        11             ---
  11       hsa-circ13156-4    0.029169   5.155549   MRPL39       26966204    26976247    −        39             ---
  12       hsa_circ0107597    0.005089   4.704399   ABCA5        67270099    67305564    −        100            6
  13       hsa_circ0061370    0.028818   4.348159   CCT8         30428647    30434877    −        73             ---
  14       hsa_circ0058143    0.027599   4.206255   FN1          216279383   216286966   −        92             3
  15       hsa_circ0003086    0.024972   4.089472   ---          64630738    65139334    \+       100            100
  16       hsa_circ0140697    0.038202   3.944226   KLHL4        86919763    86924916    \+       100            36
  17       hsa_circ0052193    0.018474   3.741495   PTPRH        55692614    55699536    −        100            87
  18       hsa_circ0140547    0.01636    3.64521    ---          73071865    73072197    \+       42             5
  19       hsa_circ0140553    0.019321   3.624559   ---          73071957    73072197    \+       38             4
  20       hsa_circ0140549    0.018403   3.623656   ---          73071909    73072197    \+       41             5
  ......                                                                                                          
  145      hsa_circ_0046285   0.046716   2.004205   PYCR1        79890268    79894968    −        100            100

###### 

MiRNAs expression profiling (*P* \< 0.05, FC ≥ 1.2).

  No.   ProbeName        *P*     FC (abs)   Regulation
  ----- ---------------- ------- ---------- ------------
  1     Hsa-miR-4299     0.016   9.07       Up
  2     Hsa-miR-20b-5p   0.033   1.29       Down
  3     Hsa-miR-363-3p   0.046   1.21       Down

ProbeName = probe address; FC = fold change; There shows miRNAs that were differentially expressed between the groups.

###### 

Differential expression of circRNAs in circRNA-miRNA network^*∗*^.

  No.   Gene expression   AMI vs UAP         CG vs AMI           CG vs UAP           CG, AMI, and UAP
  ----- ----------------- ------------------ ------------------- ------------------- -------------------
  1     Upregulated                          Hsa_circ_0140758    hsa_circ_0140758    hsa_circ_0140758
  2                                          Hsa-circ_0140759    hsa_circ_0140759    hsa-circ_0140759
  3                                          Hsa_circ_0140760    hsa_circ_0140760    hsa_circ_0140760
  4                                          Hsa_circ_16316-13   hsa-circ_16316-13   hsa_circ_16316-13
  5                                          Hsa_circ_16316-10   hsa_circ_0140736    hsa_circ_16316-10
  6                                          Hsa-circ_16316-4    hsa_circ_0140781    hsa-circ_16316-4
                                                                                     
  1     Downregulated     hsa_circ_8316-4    Hsa_circ_0140538    hsa_circ_0140538    hsa_circ_0140538
  2                       hsa-circ_0097809                       hsa_circ_0091073     
  3                       hsa_circ_0097811                                            
  4                       hsa_circ_0097810                                            
                          hsa_circ_0139861                                            

^*∗*^ *P* \< 0.05, up FC ≥ 2, down FC ≥ −2.

###### 

Analysis of the number of source genes (circRNA) and the number of target gene miRNAs.

       AMI and UAP   CG and UAP        AMI and CG   CG, AMI, and UAP                                
  ---- ------------- ----------------- ------------ ------------------ ----- ----------------- ---- --------------
  1    10            hsa-miR-6832-5p   4            hsa-miR-101-5p     5     hsa-miR-4299      15   hsa-miR-4299
  2    19            hsa-miR-1973                                      4     hsa-miR-6832-5p         
  3    13            hsa-miR-4485-3p                                   8     hsa-miR-1973            
  4    2             hsa-miR-664a-5p                                   1     hsa-miR-4485-3p         
  5    3             hsa-miR-3912-5p                                   4     hsa-miR-3912-5p         
  6    1             hsa-miR-8063                                      6     hsa-miR-8063            
  7    1             hsa-miR-3663-3p                                   4     hsa-miR-6793-5p         
  8    4             hsa-miR-1268a                                     331   hsa-miR-6749-5p         
  9    4             hsa-miR-6793-5p                                   3     hsa-miR-328-5p          
  10   1             hsa-miR-34a-5p                                    6     hsa-miR-6716-3p         
  11   1             hsa-miR-6716-3p                                   320   hsa-miR-1202            

geneSymbol is the gene abbreviation. SGS: source geneSymbol; TGS: target geneSymbol.

[^1]: Academic Editor: Ghee T. Tan
